Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:EMIS
- CUSIP: N/A
- Web: www.emisphere.com
- Market Cap: $27.23 million
- Outstanding Shares: 60,852,000
- 50 Day Moving Avg: $0.44
- 200 Day Moving Avg: $0.47
- 52 Week Range: $0.38 - $0.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Annual Revenue: $1.04 million
- Price / Sales: 26.18
- Book Value: ($2.55) per share
- Price / Book: -0.18
- EBIDTA: ($6,210,000.00)
- Net Margins: -205.51%
- Return on Assets: -28.90%
- Debt-to-Equity Ratio: -0.44%
- Current Ratio: 0.78%
- Quick Ratio: 0.78%
- Average Volume: 19,302 shs.
- Beta: 2.18
- Short Ratio: 1.65
Frequently Asked Questions for Emisphere Technologies (OTCMKTS:EMIS)
What is Emisphere Technologies' stock symbol?
Emisphere Technologies trades on the OTCMKTS under the ticker symbol "EMIS."
How were Emisphere Technologies' earnings last quarter?
Emisphere Technologies Inc. (OTCMKTS:EMIS) issued its quarterly earnings results on Friday, May, 12th. The company reported $0.04 earnings per share for the quarter. The business had revenue of $0.22 million for the quarter. View Emisphere Technologies' Earnings History.
Who are some of Emisphere Technologies' key competitors?
Some companies that are related to Emisphere Technologies include Akari Therapeutics PLC (AKTX), Fibrocell Science (FCSC), Imprimis Pharmaceuticals (IMMY), Juniper Pharmaceuticals (JNP), ContraFect Corporation (CFRX), pSivida Corp. (PSDV), KemPharm (KMPH), Zosano Pharma Corporation (ZSAN), The Joint Corp. (JYNT), Aeglea BioTherapeutics (AGLE), Microbot Medical (MBOT), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aevi Genomic Medicine (GNMX), Bellerophon Therapeutics (BLPH), Marinus Pharmaceuticals (MRNS), Ekso Bionics Holdings (EKSO) and Urogen Pharma (URGN).
Who are Emisphere Technologies' key executives?
Emisphere Technologies' management team includes the folowing people:
- Timothy G. Rothwell, Independent Chairman of the Board
- Alan L. Rubino, President, Chief Executive Officer, Director
- Alan V. Gallantar CPA, Interim Chief Financial Officer
- John D. Harkey Jr., Independent Director
- Timothy McInerney, Independent Director
- Jacob M. Plotsker, Independent Director
- Mark H. Rachesky M.D., Independent Director
- Michael Weiser M.D., Ph.D., Independent Director
How do I buy Emisphere Technologies stock?
Shares of Emisphere Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emisphere Technologies' stock price today?
MarketBeat Community Rating for Emisphere Technologies (OTCMKTS EMIS)MarketBeat's community ratings are surveys of what our community members think about Emisphere Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Emisphere Technologies stock can currently be purchased for approximately $0.45.
Consensus Ratings for Emisphere Technologies (OTCMKTS:EMIS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Emisphere Technologies (OTCMKTS:EMIS)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Emisphere Technologies (OTCMKTS:EMIS)Earnings History by Quarter for Emisphere Technologies (OTCMKTS EMIS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/12/2017||Q1 2017||$0.04||$0.22 million||View||N/A|
|3/29/2017||Q4 2016||$0.07||$0.33 million||View||N/A|
|11/14/2016||Q3 2016||($0.09)||$0.20 million||View||Listen|
|5/15/2015||Q2 2015||($0.04)||$0.01 million||View||Listen|
Earnings Estimates for Emisphere Technologies (OTCMKTS:EMIS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Emisphere Technologies (OTCMKTS:EMIS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Emisphere Technologies (OTCMKTS:EMIS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Emisphere Technologies (OTCMKTS:EMIS)
Latest Headlines for Emisphere Technologies (OTCMKTS:EMIS)
|Emisphere Technologies, Inc. :EMIS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017|
finance.yahoo.com - May 26 at 5:35 PM
|Emisphere Technologies, Inc. (EMIS) Releases Quarterly Earnings Results|
www.americanbankingnews.com - May 15 at 11:00 AM
|Emisphere Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 12 at 5:27 PM
|Investor Network: Emisphere Technologies, Inc. to Host Earnings Call|
finance.yahoo.com - May 12 at 5:27 PM
|UPDATE -- Emisphere Announces First Quarter 2017 Earnings Conference Call|
finance.yahoo.com - May 4 at 5:07 PM
|Emisphere Announces First Quarter 2017 Earnings Conference Call|
finance.yahoo.com - May 3 at 8:14 AM
|Emisphere Technologies' (EMIS) CEO Alan Rubino on Q4 2016 Results - Earnings Call Transcript|
seekingalpha.com - March 30 at 3:29 AM
|Q4 2016 Emisphere Technologies Inc Earnings Release - Before Market Open|
biz.yahoo.com - March 29 at 5:27 PM
|Form 8-K EMISPHERE TECHNOLOGIES For: Mar 29|
www.streetinsider.com - March 29 at 11:33 AM
|Something Strange Is Going On With Oral Insulin|
finance.yahoo.com - January 6 at 5:32 PM
|Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion|
www.nasdaq.com - December 9 at 5:15 PM
|Oramed Vs. Novo Nordisk In Race For Oral GLP-1|
seekingalpha.com - November 30 at 8:28 AM
|BRIEF-Emisphere Q3 loss per share $0.09|
www.reuters.com - November 14 at 5:00 PM
|Emisphere's (EMIS) CEO Alan Rubino on Q3 2016 Results - Earnings Call Transcript|
seekingalpha.com - November 14 at 5:00 PM
|Emisphere Technologies Inc Earnings Call (Q3 2016)|
biz.yahoo.com - November 14 at 5:00 PM
|Emisphere Announces Third Quarter 2016 Earnings Conference Call|
finance.yahoo.com - November 7 at 8:04 AM
|Edited Transcript of EMIS earnings conference call or presentation 15-Aug-16 12:30pm GMT|
finance.yahoo.com - August 22 at 4:54 PM
|Emisphere Technologies Inc Earnings Call (Q2 2016)|
biz.yahoo.com - August 15 at 4:57 PM
|EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial|
biz.yahoo.com - August 15 at 4:57 PM
|BRIEF-Emisphere Q2 loss per share $0.12|
www.reuters.com - August 15 at 12:02 PM
|EARNINGS SUMMARY: Details of Emisphere Technologies, Inc. Q2 Earnings Report|
www.rttnews.com - August 15 at 12:02 PM
|EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Other Events|
biz.yahoo.com - June 17 at 4:12 PM
|EMISPHERE TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - June 2 at 4:17 PM
Emisphere Technologies (EMIS) Chart for Wednesday, July, 26, 2017